Cite
A randomized, phase II trial of AEZS-108 in chemotherapy refractory triple-negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer
MLA
Charles L. Vogel, et al. “A Randomized, Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple-Negative (ER/PR/HER2-Negative) LHRH-R Positive Metastatic Breast Cancer.” Journal of Clinical Oncology, vol. 31, May 2013, p. TPS11124. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........77916ac9cb6453d8752e066646cbd967&authtype=sso&custid=ns315887.
APA
Charles L. Vogel, Reshma Mahtani, Stefan Buchholz, Alberto J. Montero, Olaf Ortmann, Andrew V. Schally, Stephan Seitz, Guenter Emons, J. Engel, & Stefan Glück. (2013). A randomized, phase II trial of AEZS-108 in chemotherapy refractory triple-negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer. Journal of Clinical Oncology, 31, TPS11124.
Chicago
Charles L. Vogel, Reshma Mahtani, Stefan Buchholz, Alberto J. Montero, Olaf Ortmann, Andrew V. Schally, Stephan Seitz, Guenter Emons, J. Engel, and Stefan Glück. 2013. “A Randomized, Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple-Negative (ER/PR/HER2-Negative) LHRH-R Positive Metastatic Breast Cancer.” Journal of Clinical Oncology 31 (May): TPS11124. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........77916ac9cb6453d8752e066646cbd967&authtype=sso&custid=ns315887.